Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review
Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review
Background: non-small cell lung cancer (NSCLC) remains a major global health problem because of its prevalence and poor prognosis. Treatment options are limited and there is a need to explore alternatives. This systematic review evaluates the role of Chinese herbal medicine (CHM) in association with chemotherapy for NSCLC.
Methods: english and Chinese databases were searched for RCTs comparing CHM with conventional biomedical treatment or placebo. Papers were reviewed systematically and data were analysed using standard Cochrane software Revman 5.
Results: fifteen Chinese trials involving 862 participants met the inclusion criteria. All trials were of poor quality with a considerable risk of bias. There was a significant improvement in quality of life (QoL) (increased Karnofsky Performance Status) (RR 1.83, 95% CI 1.41-2.38, p<0.00001 for both stages III, IV only NSCLC and all stages NSCLC) and less anaemia (RR 0.37, 95% CI 0.15-0.91, p=0.03 for stages III, IV only NSCLC; p=0.005 for all stages NSCLC) and neutropenia (RR 0.42, 95% CI 0.22-0.82, p=0.01 for stages III, IV only NSCLC; p<0.00001 for all stages NSCLC) when CHM is combined with chemotherapy compared to chemotherapy alone. There was no significant difference in short term effectiveness and limited inconclusive data concerning long term survival. Five promising herbs have been identified.
Conclusion: it is possible that oral CHM used in conjunction with chemotherapy may improve QoL in NSCLC. This needs to be examined further with more rigorous methodology.
Chinese herbal medicine, systematic review, complementary medicine, non-small cell lung cancer
137-145
Chen, Sisi
9510418a-cae8-468c-a30e-7329d8bd18c8
Flower, Andrew
5256a2c8-6e74-49be-acc8-463ed3c18c6a
Ritchie, Andrew
98e87f92-33f5-42d8-9f00-8dec3c9bd757
Liu, Jianping
4699004b-2872-49f2-b2f9-f90a061a29db
Molassiotis, Alex
f4f18817-07cb-48ca-a51e-9504aa886a79
He, Yu
50c6db3a-8a30-4d25-b97f-bf79cdc68175
Lewith, George
0fc483fa-f17b-47c5-94d9-5c15e65a7625
2010
Chen, Sisi
9510418a-cae8-468c-a30e-7329d8bd18c8
Flower, Andrew
5256a2c8-6e74-49be-acc8-463ed3c18c6a
Ritchie, Andrew
98e87f92-33f5-42d8-9f00-8dec3c9bd757
Liu, Jianping
4699004b-2872-49f2-b2f9-f90a061a29db
Molassiotis, Alex
f4f18817-07cb-48ca-a51e-9504aa886a79
He, Yu
50c6db3a-8a30-4d25-b97f-bf79cdc68175
Lewith, George
0fc483fa-f17b-47c5-94d9-5c15e65a7625
Chen, Sisi, Flower, Andrew, Ritchie, Andrew, Liu, Jianping, Molassiotis, Alex, He, Yu and Lewith, George
(2010)
Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review.
Lung Cancer, 68, .
(doi:10.1016/j.lungcan.2009.11.008).
Abstract
Background: non-small cell lung cancer (NSCLC) remains a major global health problem because of its prevalence and poor prognosis. Treatment options are limited and there is a need to explore alternatives. This systematic review evaluates the role of Chinese herbal medicine (CHM) in association with chemotherapy for NSCLC.
Methods: english and Chinese databases were searched for RCTs comparing CHM with conventional biomedical treatment or placebo. Papers were reviewed systematically and data were analysed using standard Cochrane software Revman 5.
Results: fifteen Chinese trials involving 862 participants met the inclusion criteria. All trials were of poor quality with a considerable risk of bias. There was a significant improvement in quality of life (QoL) (increased Karnofsky Performance Status) (RR 1.83, 95% CI 1.41-2.38, p<0.00001 for both stages III, IV only NSCLC and all stages NSCLC) and less anaemia (RR 0.37, 95% CI 0.15-0.91, p=0.03 for stages III, IV only NSCLC; p=0.005 for all stages NSCLC) and neutropenia (RR 0.42, 95% CI 0.22-0.82, p=0.01 for stages III, IV only NSCLC; p<0.00001 for all stages NSCLC) when CHM is combined with chemotherapy compared to chemotherapy alone. There was no significant difference in short term effectiveness and limited inconclusive data concerning long term survival. Five promising herbs have been identified.
Conclusion: it is possible that oral CHM used in conjunction with chemotherapy may improve QoL in NSCLC. This needs to be examined further with more rigorous methodology.
This record has no associated files available for download.
More information
Published date: 2010
Keywords:
Chinese herbal medicine, systematic review, complementary medicine, non-small cell lung cancer
Identifiers
Local EPrints ID: 73657
URI: http://eprints.soton.ac.uk/id/eprint/73657
ISSN: 0169-5002
PURE UUID: 7d883cca-02a8-48bd-88ae-082667bc21a8
Catalogue record
Date deposited: 16 Mar 2010
Last modified: 13 Mar 2024 22:13
Export record
Altmetrics
Contributors
Author:
Sisi Chen
Author:
Andrew Flower
Author:
Andrew Ritchie
Author:
Jianping Liu
Author:
Alex Molassiotis
Author:
Yu He
Author:
George Lewith
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics